Analytical Data
-
基因名
CGI-121
- Application
-
别名
CGI 121 ; My019 ; PRPK (p53 related Protein kinase) binding Protein ; PRPK-binding Protein; TP53RK binding Protein; TP53RK-binding Protein; Tprkb; TPRKB_HUMAN
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9Y3C4
-
表达区间
1-175aa
-
氨基酸序列
MQLTHQLDLFPECRVTLLLFKDVKNAGDLRRKAMEGTIDGSLINPTVIVDPFQILVAANKAVHLYKLGKMKTRTLSTEIIFNLSPNNNISEALKKFGISANDTSILIVYIEEGEKQINQEYLISQVEGHQVSLKNLPEIMNITEVKKIYKLSSQEESIGTLLDAIICRMSTKDVL
-
分子量
46.1 KDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CGI-121 is a recombinant protein that has garnered significant attention in the field of biomedical research due to its potential applications in cancer therapy and immunology. As a member of the C-type lectin receptor family, CGI-121 plays a pivotal role in mediating immune responses and modulating inflammation. Its unique structural properties allow it to interact with specific carbohydrate patterns on the surface of pathogens and tumor cells, thereby influencing immune cell activation and cytokine production. Recent studies have indicated that CGI-121 may enhance the efficacy of existing cancer treatments by promoting anti-tumor immunity and reducing immune evasion by tumors. Additionally, research has explored its potential as a therapeutic target, leading to the development of novel drugs that can either mimic or inhibit its function. The ongoing investigation into the biological mechanisms and clinical implications of CGI-121 is paving the way for innovative approaches to treat various cancers and autoimmune diseases. Overall, the study of CGI-121 is essential for advancing our understanding of immune regulation and improving therapeutic strategies.
